AMGN: AMGEN Inc. Company Profile & Statistics

About

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

Info & Links

CEO

Robert A. Bradway

Headquarters

ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CA 91320, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

4,614

Employees

26,700

AMGEN Inc. Statistics

Valuation Measures

Market Capitalization²

141.62B

Enterprise Value

193.00B

Enterprise Value/EBITDA(ttm)

16.37

Price to Earnings Ratio(ttm)

13.59

Price to Sales(ttm)

4.32

Price to Book(mrq)

18.65

Price to Cash(ytd)

9.91

Profitability

Gross Margin(ttm)

60.39%

Operating Margin(ttm)

31.96%

Profit Margin(ttm)

12.50%

Return on Equity(ttm)

168.35%

Return on Invested Capital(ttm)

6.51%

Return on Assets(ttm)

11.18%

Income Statement

Revenue(ttm)

32.53B

Revenue Per Share(ttm)

60.52

Gross Profit(ttm)

19.68B

EBITDA(ttm)³

11.79B

Net Income Available to Common(ttm)

4.23B

Diluted EPS(ttm)

7.81

Share Statistics

Beta (5Y Monthly)

0.55

52-Week Change

-0.41%

S&P 500 52-Week Change

24.74%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

537.53M

Dividend Yield

3.45%

Float⁴

533.82M

% Held by Insiders

0.69%

% Held by Institutions

76.50%

Balance Sheet

Total Cash(mrq)

9.01B

Total Cash Per Share(mrq)

16.76

Total Debt(mrq)

60.40B

Total Debt/Equity(mrq)

802.42%

Current Ratio(mrq)

1.32%

Quick Ratio(mrq)

0.96%

Book Value Per Share(mrq)

14.00

Cash Flow

Operating Cash Flow Per Share(ytd)

12.40

Free Cash Flow(ytd)

5.99B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

AMGN

AMGEN Inc.

AMGEN Inc. Profile